TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03905317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent chemotherapy
Description: weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
Study: NCT02262442

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enk Fiberoptic Atomizer
Description: Nebulization of local anesthetics with the Enk Fiberoptic Atomizer by Cook Medical during the flexible bronchoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bronchoscope
Description: Standard procedure: Administration of local anesthetics via the working channel of the bronchoscope during the flexible bronchoscopy
Study: NCT01545232

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 1:1:1 Blood Transfusion Ratio
Description: Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC; the blood bank will send the initial and all subsequent containers until notified of the discontinuation of the PROPPR transfusion protocol.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 1:1:2 Blood Transfusion Ratio
Description: Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units platelets and 6 units RBC, a second container containing 3 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC, and the blood bank will send this sequence of 2 containers repeatedly, until notified of the discontinuation of the PROPPR transfusion protocol.
Study: NCT03069287

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benjamin Rose Institute (BRI) Care Consultation™ Program
Description: The BRI Care Consultation™ can be delivered via face-to-face contact, telephone, mail, and/or email by a Care Consultant and caregiver who assists with daily activities, tasks, and health-related issues. BRI CareConsultation™ uses a secure, web-based Care Consultation Information System (CCIS) to guide the delivery of the intervention.
Study: NCT02071186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality training
Description: Subjects will train with the VR system at the Tel Aviv Sourasky Medical Center 3 times per week for 6 weeks with each session lasting approximately 30 minutes.~To assure participants' safety and maintaining progress, training with the VR will be individual and provided by qualified physiotherapists, who use the system on a daily basis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Remediation
Description: Subjects in this study will train with the AttenGo program at home 3-5 times per week for 6 weeks with each session lasting approximately 30 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Study: NCT01377948

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ACT with RAGE-Control
Description: This is an open trial of ACT with RAGE-Control which is a behavioral intervention. The therapy involves five psychotherapy sessions taking place over five consecutive days.
Study: NCT02036736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraoperative anesthetic strategy by Propofol
Description: 1- Arm Propofol: Propofol TCI induction target between 2 and 6 mg / mL~* Sufentanil (0.15 mg / kg intravenously (IV))~* Atracurium (0.5 mg / kg IV) Maintenance mode by Propofol TCI target between 2 and 4 micrograms / mL tune to 40 \<BIS \<60 Sufentanil bolus according to intraoperative analgesia Atracurium bolus according to the level of neuromuscular blockade

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraoperative anesthetic strategy by Desflurane
Description: 2- Arm Desflurane Desflurane induction (2-3 mg / kg)~* Sufentanil (0.15 mg / kg IV)~* Atracurium (0.5 mg / kg IV)) Desflurane closed by maintenance target with minimal alveolar concentration (MAC) to adapt the circuit to obtain a figure 40 \<BIS \<60 Sufentanil bolus according to intraoperative analgesia Atracurium bolus according to the level of neuromuscular blockade
Study: NCT01499550

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: humidified transnasal insufflation (TNI20oxy)
Description: The alternative breathing support with TNI supplies COPD patients with 20L/min of warm humidified air. This method may be applicable to wash out the dead space between glottis and nasal opening. Pre-investigations have shown that 45 minutes of TNI during daytime reduced PCO2 and respiratory rate compared to application of oxygen alone.Transcutaneous PCO2 is measured over night. A capillary blood gas analysis (BGA) is carried out at beginning and end of each measurement night.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: overnight oxygen treatment with individual flow rate
Description: The patient is treated with his individual oxygene flow rate. Transcutaneous PCO2 is measured over night. A capillary blood gas analysis (BGA) is carried out at beginning and end of each measurement night.
Study: NCT04466254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPGJ602
Description: Q2W/QW iv
Study: NCT00378599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of (a) pegylated interferon alfa-2b and (b) rebetol
Description: 1. Powder for injection in vials and Redipen (50, 80, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks~2. 200 mg capsules, oral, weight based dose of 400-1200 mg, daily for up to 48 weeks
Study: NCT02462408

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior approach
Description: The needle insertion point was over the trapezius muscle sufficiently posterior to allow the needle to pass between the clavicle and the scapula in the direction of the axillary artery. The insertion point was strictly aligned with the long axis of the ultrasound beam i.e. in-plane technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional approach
Description: The needle insertion point would be at the cephalad (lateral) aspect of the ultrasound probe, beneath the clavicle and medial to the coracoid process. The insertion point was strictly aligned with the long axis of the ultrasound beam i.e. in-plane technique.
Study: NCT00489736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dronedarone (SR33589)
Description: oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amiodarone
Description: oral administration
Study: NCT04021524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzoyl Peroxide 10% Bar
Description: Patients will wash with Benzoyl Peroxide 10% Bar

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Gluconate
Description: Patients will wash with Chlorhexidine Gluconate
Study: NCT04172168

Intervention type: DIAGNOSTIC_TEST
Intervention: Heart rupture
Description: Left ventricular free-wall ruptrue after AMI
Study: NCT04466254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPGJ602
Description: Q2W/QW iv

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: QW iv
Study: NCT03109301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib (AZD6244 hyd sulfate) 50mg/dose
Description: Selumetinib will be administered at a starting dose of 50 mg/dose orally in patients 18 years or older; drug will be given twice daily continuously in the absence of toxicity or disease progression, using 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib (AZD6244 hyd sulfate) 25mg/m2
Description: Selumetinib will be administered at a starting dose of 25 mg/m2/dose in children \< 18 years of age; drug will be given twice daily continuously in the absence of toxicity or disease progression, using 28-day cycles.
Study: NCT04493281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: Oral suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MCI-186
Description: Intravenous formulation
Study: NCT02707393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: infusion, orally if possible

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bone marrow or peripheral blood stem cells
Description: infusion
Study: NCT04526873

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postcard
Description: Mailed
Study: NCT03733691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: 3 mg oral capsule, Days 1, 8 and 15 of 28-day cycles
Study: NCT04526873

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postcard
Description: Mailed

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postcard
Description: Mailed

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postcard
Description: Mailed

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone call
Description: May be automated or by human

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Humor/Salience
Description: Funny cartoon + health risk examples
Study: NCT03733691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: 3 mg oral capsule, Days 1, 8 and 15 of 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Same dose as in the front-line treatment in the last treatment cycle, taken orally, on days 1-28 of a 28-day cycle.
Study: NCT00934154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 100 mg/day continuously for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan+Prednisolone
Description: Melphalan 2 mg, Prednisolone 16 mg
Study: NCT04526873

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Humor/Salience
Description: Funny cartoon + health risk examples

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth
Description: Information about video visit

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth
Description: Information about video visit
Study: NCT00934154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan+Prednisolone
Description: Melphalan 2 mg, Prednisolone 16 mg
Study: NCT02670954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine, tramadol and flurbiprofen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tramadol and flurbiprofen
Study: NCT03279523

Intervention type: DRUG
Intervention: F 18 T807
Description: Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
Study: NCT04447599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: photography of conjunctival vessels
Description: patient will have photo of their bulbar conjunctival of each eye and photography of fundus without dilatation
Study: NCT01307202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 600mg of Gabapentin will be given orally preoperatively and 200mg for 3 times a day after surgery for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will match the the gabapentin pill and will be given orally.
Study: NCT01678352

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Lysate Vaccine
Description: Cohort 1 Cohort 2 Cohort 3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Lysate Vaccine
Description: Cohort 1 Cohort 2 Cohort 3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Lysate Vaccine
Description: Cohort 1 Cohort 2 Cohort 3
Study: NCT02305108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fascial manipulation
Description: Recruited patients in study's group will be treated with the standard treatment and fascial manipulation.~Specific points of fascial tissue will be treated with a deep friction to improve elasticity.~The number of point treated will be refered to a specific evaluation for each patient.~Fascial manipulation provide 3 session treatment (one treatment for week).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: Before surgery, standard physiotherapy treatment provides an education session about the rehabilitation program tha is going to be execute after surgery.~After surgery 2 daily physiotherapy treatment are implemented: bed exercise as active and passive flex-extension of lower limb, movements for postural change to reach sitting and standing position, walking training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: Before surgery, standard physiotherapy treatment provides an education session about the rehabilitation program tha is going to be execute after surgery.~After surgery 2 daily physiotherapy treatment are implemented: bed exercise as active and passive flex-extension of lower limb, movements for postural change to reach sitting and standing position, walking training.
Study: NCT01207765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indium-111-ibritumomab tiuxetan
Description: 1.5mg of 111In Zevalin (containing 5 mCi of 111In) will be used for radioimaging. 111In Zevalin will be administered by a 10 minute slow IV push injection immediately following completion of the rituximab infusion. 111In Zevalin may be injected by stopping the flow from the IV bag and injecting the radiolabeled antibody directly into the IV line. A 0.22 micron filter must be on line between the drug infusion port and the patient. The line must be flushed with at least 10cc of normal saline after 111In Zevalin has been injected.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Y Zevalin
Description: Each patient will receive a single therapeutic dose of 90Y Zevalin at a dose of 0.4 mCi/kg, capped at a maximum dose of 32 mCi. 90Y Zevalin will be administered intravenously as a slow IV push over 10 minutes. 90Y Zevalin may be directly infused by stopping the flow from the IV bag and injecting the radiolabeled antibody directly into the IV line. A 0.22 micron filter must be on line between the syringe and the infusion port. The line must be flushed with at least 10cc normal saline after 90Y Zevalin has been infused.
Study: NCT01969240

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chest Pain Choice Decision Aid
Description: The clinician will review the decision aid with the patient. The decision aid will be used as a tool to facilitate discussion and educate the patient regarding the rationale for their evaluation up to that point in the emergency department visit and their individual risk for a heart attack or pre-heart attack. The clinician will provide the patient with management options consistent with both the patient's values and preferences and the clinician's level of comfort.
Study: NCT05571241

Intervention type: BEHAVIORAL
Intervention: Fast rehabilitation program
Description: 1-2 weeks (first post-op visit): Long thumb spica splint removed; Staples/stitches removed; Short hand-based thumb spica fitted for the patient Start Active Range of Motion Exercises (AROM) for thumb Add active assisted rang of motion exercises (AAROM) if no significant progress 6 weeks: Gradually wean off of splint during the day; wear for protection and/or more strenuous daily activities 6-8 weeks: Passive Range of Motion Exercises (PROM) (ie. stretching), if needed - (ie. No significant changes in ROM of thumb) 8-10 weeks: Resisted exercises/activities without splint on
Study: NCT04436185

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comparisons of procedural pain
Description: This randomized experimental study with placebo and control groups

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comparisons of procedural pain
Description: This randomized experimental study with placebo and control groups
Study: NCT02557698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balneum oil bath
Study: NCT00745147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese herbal formula (CCH1)
Description: initial dose of 1.5/3.0/4.5gm herbal powder with 15/30/45ml placebo of duphalac, respectively, per day for mild/moderate/severe constipation, then titrated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duphalac
Description: initial dose of 15/30/45ml duphalac with 1.5/3.0/4.5gm placebo of herbal powder, respectively, per day for mild/moderate/severe constipation, then titrated
Study: NCT02040454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Standard Therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Study: NCT02561650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COV155
Description: COV155 tablets
Study: NCT01678352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Cohort 1 Cohort 2 Cohort 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Cohort 1 Cohort 2 Cohort 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Cohort 1 Cohort 2 Cohort 3
Study: NCT01335841

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Navigation station coupled with a 3D fluoroscopy
Description: After randomization, patients will be operated with the conventional method either with navigation station. In the conventional method, the orthopedic surgeon based on anatomical criteria to establish its implants. It uses an image intensifier in 2D mode to monitor the implementation of the implants. In computer assisted surgery, the surgeon uses a navigation station that allows real-time flow instruments to guide its implementation of the implants. It uses an image intensifier in 3D mode on the one hand to achieve a first series of image that will be used for navigation and also to monitor the implementation of the implants.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navigation station coupled with a 3D fluoroscopy
Description: After randomization, patients will be operated with the conventional method either with navigation station. In the conventional method, the orthopedic surgeon based on anatomical criteria to establish its implants. It uses an image intensifier in 2D mode to monitor the implementation of the implants. In computer assisted surgery, the surgeon uses a navigation station that allows real-time flow instruments to guide its implementation of the implants. It uses an image intensifier in 3D mode on the one hand to achieve a first series of image that will be used for navigation and also to monitor the implementation of the implants.
Study: NCT01612650

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tomosynthesis
Description: 2 incidences 3D numeric mammography

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tomosynthesis
Description: 2 incidences 3D numeric mammography

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tomosynthesis
Description: 2 incidences 3D numeric mammography
Study: NCT03707314

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Angiography with follow-on revascularisation if indicated
Description: Angiography with follow-on revascularisation (if indicated)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Angiography with follow-on revascularisation if indicated
Description: Angiography with follow-on revascularisation (if indicated)
Study: NCT00232817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine (drug)
Description: nicotine nasal spray (3mg) before surgery
Study: NCT01424267

Intervention type: DEVICE
Intervention: Zenith® Low Profile AAA Endovascular Graft
Description: Treatment of an abdominal aortic or aorto-iliac aneurysm with the CE-marked Zenith(R) Low Profile AAA Endovascular Graft.
Study: NCT03506828

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical sympathectomy
Description: thoracoscopic sympathectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation with phenol injection
Description: All patient in this group will have radiofrequency ablation of T2 and T3 sympathetic ganglia with phenol injection
Study: NCT04225351

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MCAF+CM
Description: CAF procedure + collagen matrix

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MCAT+CM
Description: Tunnel procedure + collagen matrix
Study: NCT03657758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPA and rosuvastatin
Description: To take EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for ９ months.
Study: NCT06124170

Intervention type: PROCEDURE
Intervention: Preoperative pain managment
Description: propaganda and education on pain; Preemptive analgesia with celecoxib (200 mg bid) 2 days before surgery

Intervention type: PROCEDURE
Intervention: Preoperative pain managment
Description: propaganda and education on pain; Preemptive analgesia with celecoxib (200 mg bid) 2 days before surgery
Study: NCT01808573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lapatinib
Study: NCT04600258

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dark Chocolate
Description: The patients will receive 40g per day of dark chocolate for 2 months
Study: NCT01148615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (AVE0005)
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study: NCT03657758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose rosuvastatin
Description: To take high dose rosuvastatin (10mg/day) for ９ months.
Study: NCT02671591

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI-PrEP
Description: This is a one-hour motivational interviewing-based, one-to-one session that will help YBMSM think more about going on PrEP and it will help YBMSM think more about using condoms consistently and correctly with every sex partner.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control condition
Description: This is a behavioral program designed to provide men with condoms and lubricants that make sex feel good even though it is fully protected by latex condoms